{"id":29602,"date":"2026-01-12T04:41:00","date_gmt":"2026-01-11T20:41:00","guid":{"rendered":"https:\/\/csccm.org.cn\/?p=29602"},"modified":"2026-01-12T05:47:11","modified_gmt":"2026-01-11T21:47:11","slug":"jama%e5%8f%91%e8%a1%a8%e8%ae%ba%e6%96%87%ef%bc%9a%e9%a5%ae%e7%94%a8%e6%88%96%e7%a6%81%e7%94%a8%e5%90%ab%e5%92%96%e5%95%a1%e5%9b%a0%e7%9a%84%e5%92%96%e5%95%a1%e4%bb%a5%e5%87%8f%e5%b0%91%e6%88%bf","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=29602","title":{"rendered":"[JAMA\u53d1\u8868\u8bba\u6587]\uff1a\u996e\u7528\u6216\u7981\u7528\u542b\u5496\u5561\u56e0\u7684\u5496\u5561\u4ee5\u51cf\u5c11\u623f\u98a4"},"content":{"rendered":"\n

Original Investigation <\/p>\n\n\n\n

Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation: The DECAF Randomized Clinical Trial<\/h1>\n\n\n\n

Christopher X. Wong, Christopher C. Cheung, Gabrielle Montenegro, et al<\/h3>\n\n\n\n

JAMA Published Online: November 9, 2025<\/h3>\n\n\n\n

doi: 10.1001\/jama.2025.21056<\/h3>\n\n\n\n

Key Points<\/p>\n\n\n\n

Question<\/strong>  Does consumption of caffeinated coffee have a beneficial, detrimental, or neutral effect on the risk of recurrent atrial fibrillation (AF) episodes?<\/p>\n\n\n\n

Findings<\/strong>  In this multicenter randomized clinical trial including 200 patients with persistent AF undergoing cardioversion, the risk of recurrent AF was significantly lower in the group allocated to coffee consumption (47%) compared with the abstinence group (64%).<\/p>\n\n\n\n

Meaning<\/strong>  Consumption of coffee and other caffeinated products may be reasonably considered in patients with AF.<\/a><\/p>\n\n\n\n

Abstract<\/p>\n\n\n\n

Importance<\/strong>  Conventional wisdom holds that caffeinated coffee is proarrhythmic. Coffee is the most commonly consumed caffeinated beverage in the US, and a randomized trial assessing caffeinated coffee consumption in patients with atrial fibrillation (AF) has not previously been performed.<\/p>\n\n\n\n

Objective<\/strong>  To determine the effect of caffeinated coffee consumption compared with abstinence from coffee and caffeine on recurrent AF.<\/p>\n\n\n\n

Design, Setting, and Participants<\/strong>  This was a prospective, open-label, randomized clinical trial enrolling 200 current or previous (within past 5 years) coffee-drinking adults with persistent AF, or atrial flutter with a history of AF, planned for electrical cardioversion from 5 hospitals in the US, Canada, and Australia between November 2021 and December 2024. The date of final follow-up was June 5, 2025.<\/p>\n\n\n\n

Intervention<\/strong>  Patients were randomized in a 1:1 ratio to regular caffeinated coffee consumption vs coffee and caffeine abstinence for 6 months. Patients in the coffee consumption group were encouraged to drink at least 1 cup of caffeinated coffee daily. Patients in the abstinence group were encouraged to completely abstain from both caffeinated and decaffeinated coffee and other caffeine-containing products.<\/p>\n\n\n\n

Main Outcomes and Measures<\/strong>  The primary end point was clinically detected recurrence of AF or atrial flutter over 6 months.<\/p>\n\n\n\n

Results<\/strong>\u00a0\u00a0Two hundred patients (mean [SD] age, 69 [11] years; 71% male) were randomized to caffeinated coffee consumption (n\u2009=\u2009100) or coffee abstinence (n\u2009=\u2009100). Baseline coffee intake was 7 cups (IQR, 7-18) per week in both groups. During follow-up, coffee intake in the consumption and abstinence groups was 7 (IQR, 6-11) and 0 (IQR, 0-2) cups per week, respectively, resulting in a between-group difference of 7 cups (95% CI, 7-7) per week. In the primary analysis, AF or atrial flutter recurrence was less in the coffee consumption (47%) than the coffee abstinence (64%) group, resulting in a 39% lower hazard of recurrence (hazard ratio, 0.61 [95% CI, 0.42-0.89];\u00a0P<\/em>\u2009=\u2009.01). A comparable benefit of coffee consumption was observed with AF recurrence only. There was no significant difference in adverse events.<\/p>\n\n\n\n

\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n

Conclusions and Relevance<\/strong>  In this clinical trial of coffee drinkers after successful cardioversion, allocation to consumption of caffeinated coffee averaging 1 cup a day was associated with less recurrence of AF or atrial flutter compared with abstinence from coffee and caffeinated products.<\/p>\n\n\n\n

Trial Registration<\/strong>  ClinicalTrials.gov Identifier: NCT05121519<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Original Investigation  Caffeinated Coffee Consump […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/29602"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=29602"}],"version-history":[{"count":2,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/29602\/revisions"}],"predecessor-version":[{"id":29901,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/29602\/revisions\/29901"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=29602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=29602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=29602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}